Oklahoma State Supreme Court Rules in Favor of Johnson & Johnson in Opioid Litigation

NEW BRUNSWICK, N.J., November 9, 2021 - The Oklahoma State Supreme Court today ruled in favor of Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies in overturning the trial court’s $465 million judgment in 2019. The Court appropriately and categorically rejected the misguided and unprecedented expansion of the public nuisance law as a means to regulate the manufacture, marketing, and sale of products, including the Company’s prescription opioid medications. We recognize the opioid crisis is a tremendously complex public health issue, and we have deep sympathy for everyone affected. The Company’s actions relating to the marketing and promotion of these important prescription opioid medications were appropriate and responsible. The Company no longer sells prescription opioid medications in the United States as part of our ongoing efforts to focus on transformational innovation and serving unmet patient needs.For more information, visit www.FactsAboutOurPrescriptionOpioids.com.Cautions Concerning Forward-Looking StatementsThis statement contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding opioid litigation. The reader is cautioned not to rely on these forward-looking statements. The information contained in this statement is for informational purposes only and should not be construed as a commitment by the Company to engage in any specific strategy or course of action. Due to the inher...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news